
|Videos|March 3, 2022
Combination neoadjuvant nivolumab/gemcitabine-cisplatin is efficacious in pathologically downstaging MIBC
Author(s)Urology Times staff
“The complete response rates were 49%, which is quite impressive compared to historical controls,” says Shilpa Gupta, MD.
Advertisement
In this video, Shilpa Gupta, MD, discusses the background and findings of the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Jessica Yih, MD, highlights data on testosterone therapy in women
2
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
3
Higher intake of ultra-processed food associated with increased prostate cancer risk
4
Narmina Khanmammadova, MD, discusses findings on pelvic floor therapy before HoLEP
5









